267 related articles for article (PubMed ID: 35026721)
1. Vaccination against Her-2/neu, with focus on peptide-based vaccines.
Tobias J; Garner-Spitzer E; Drinić M; Wiedermann U
ESMO Open; 2022 Feb; 7(1):100361. PubMed ID: 35026721
[TBL] [Abstract][Full Text] [Related]
2. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
3. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
4. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
6. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.
Kaumaya PT
Future Oncol; 2020 Aug; 16(23):1767-1791. PubMed ID: 32564612
[TBL] [Abstract][Full Text] [Related]
7. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
8. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
9. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
Riemer AB; Klinger M; Wagner S; Bernhaus A; Mazzucchelli L; Pehamberger H; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Immunol; 2004 Jul; 173(1):394-401. PubMed ID: 15210798
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.
Mohit E; Hashemi A; Allahyari M
Expert Rev Clin Immunol; 2014 Jul; 10(7):927-61. PubMed ID: 24867051
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.
Tobias J; Högler S; Raigel M; Lin DS; Chao Y; Kenner L; Garner-Spitzer E; Yavrom S; Ede NJ; Zielinski CC; Kundi M; Wiedermann U
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203458
[TBL] [Abstract][Full Text] [Related]
15. Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.
Tobias J; Drinić M; Högler S; Ambroz K; Baier K; Kodajova P; Tomasich E; Berghoff AS; Schmid A; Garner-Spitzer E; Kenner L; Kundi M; Zielinski CC; Wiedermann U
Transl Oncol; 2022 May; 19():101378. PubMed ID: 35259675
[TBL] [Abstract][Full Text] [Related]
16. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
17. Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.
Tobias J; Drinić M; Schmid A; Hladik A; Watzenböck ML; Battin C; Garner-Spitzer E; Steinberger P; Kundi M; Knapp S; Zielinski CC; Wiedermann U
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428769
[TBL] [Abstract][Full Text] [Related]
18. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
19. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
20. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
